KV Pharmaceutical Company to market new generic drugs in U.S. via exclusive deal with Gedeon Richter
The products will serve the Cardiovascular, Diabetic and Central Nervous System markets, including psychotropic categories. Subject to FDA approval and patent expirations, KV expects that the products will enter the U.S. marketplace over the next several years through 2017. The estimated branded annual sales volume value of the products - based on 2005 IMS data - is approximately $20 billion. Two of the products are already filed with the FDA and a third is expected to be filed shortly.
Under terms of the agreement, Gedeon Richter will have responsibility for the development, manufacturing and regulatory requirements of the products. Gedeon Richter will receive a share of the revenues. Specific terms of the agreement were not disclosed.
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.